CDNA
CareDx, Inc.
Price Chart
Latest Quote
$26.18
+2.70 (+11.50%)
Current Price
| Previous Close | $23.48 |
| Open | $23.93 |
| Day High | $26.26 |
| Day Low | $23.93 |
| Volume | 2,744,381 |
Stock Information
| Shares Outstanding | 51.66M |
| Total Debt | $24.50M |
| Cash Equivalents | $187.18M |
| Revenue | $412.82M |
| Net Income | $-8.19M |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Market Cap | $1.35B |
| EPS (TTM) | $-0.16 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.04B |
| Sales | $412.82M |
| Income | $-8.19M |
| Book/sh | $6.12 |
| Cash/sh | $3.62 |
| Employees | 761 |
Financial Ratios
| Quick Ratio | 2.93 |
| Current Ratio | 3.40 |
| Debt/Eq | 7.81 |
Returns & Margins
| ROA | -1.80% |
| ROE | -2.37% |
| Gross Margin | 68.88% |
| Operating Margin | 1.53% |
| Profit Margin | -1.98% |
Ownership
| Insider Ownership | 3.38% |
| Institutional Ownership | 101.85% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 23.09 |
| P/S | 3.28 |
| P/B | 4.28 |
Analyst Data
| Recommendation | buy |
| Target Price | $25.80 |
Technical Indicators
| SMA20 | $22.84 |
| SMA50 | $21.37 |
| SMA200 | $18.34 |
| RSI | 66.41 |
| ATR | 1.3254 |
| Shares Float | 49.28M |
| Short Float | 12.56% |
| Short Ratio | 8.96 |
| Volatility | 2.48 |
| Rel Volume | 3.23 |
Performance History
| Week | +10.65% |
| Month | +27.52% |
| Quarter | +48.83% |
| 6 Months | +35.23% |
| YTD | +36.78% |
| Year | +34.12% |
| 3 Years | +213.16% |
| 5 Years | -71.31% |
| 10 Years | +408.35% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $26.18 | 2,744,500 |
| 2026-06-17 | $23.48 | 970,600 |
| 2026-06-16 | $23.25 | 938,000 |
| 2026-06-15 | $24.08 | 903,400 |
| 2026-06-12 | $22.97 | 769,100 |
| 2026-06-11 | $23.66 | 839,500 |
| 2026-06-10 | $23.46 | 757,000 |
| 2026-06-09 | $22.75 | 754,500 |
| 2026-06-08 | $21.95 | 366,100 |
| 2026-06-05 | $22.25 | 548,400 |
| 2026-06-04 | $23.12 | 1,604,000 |
| 2026-06-03 | $22.31 | 700,300 |
| 2026-06-02 | $22.07 | 904,000 |
| 2026-06-01 | $22.80 | 598,900 |
| 2026-05-29 | $22.82 | 685,300 |
| 2026-05-28 | $22.70 | 773,400 |
| 2026-05-27 | $22.16 | 472,900 |
| 2026-05-26 | $21.54 | 476,900 |
| 2026-05-22 | $21.63 | 522,100 |
| 2026-05-21 | $21.57 | 670,300 |
| 2026-05-20 | $21.15 | 1,320,600 |
| 2026-05-19 | $20.53 | 589,400 |
About CareDx, Inc.
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. It also offers HeartCare, which provides information about distinct biological processes, such as immune quiescence, active injury, acute cellular rejection, and antibody mediated rejection; HistoMap Kidney, a solution that identifies allograft rejection and type of rejection in kidney transplant biopsy tissue; and AlloHeme, a monitoring test that predicts relapse in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, the company provides QTYPE that enables precision in human leukocyte antigen (HLA) typing; Olerup SSP, which is used to type HLA alleles based on sequence specific primer technology; and Ottr, a transplant patient management software. Further, it offers AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a solution that monitors the pharmacokinetics of engraftment and persistence of cells for patients who have received allogeneic cell therapy; and XynQAPI, MedActionPlan, CareDx pharmacy, AlloHome, and HLA Data Systems software solutions. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.
đ° Latest News
CareDx (CDNA) Moves 11.5% Higher: Will This Strength Last?
Zacks âĸ 2026-06-19T11:39:00Z
CareDx (CDNA) Valuation Check After Choppy Trading And Growing AI Diagnostics Story
Simply Wall St. âĸ 2026-06-09T14:11:25Z
CareDx Sharpens Precision Diagnostics Push With Naveris Deal, AlloHeme Plans
MarketBeat âĸ 2026-06-09T00:03:15Z
CareDx Highlights 39% Q1 Growth, Naveris Oncology Push at Jefferies
MarketBeat âĸ 2026-06-07T10:03:50Z
A Look At CareDx (CDNA) Valuation After Recent Share Price Momentum Cools
Simply Wall St. âĸ 2026-05-04T23:15:29Z
CareDx, Inc Q1 2026 Earnings Call Summary
Moby âĸ 2026-04-29T12:30:00Z
CareDx Inc (CDNA) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansion
GuruFocus.com âĸ 2026-04-29T07:10:02ZCareDx to Acquire Naveris to Expand Into Cancer MRD Testing
Exec Edge âĸ 2026-04-29T00:41:03Z
CareDx Q1 Earnings Call Highlights
MarketBeat âĸ 2026-04-28T22:47:33Z
CareDx (CDNA) Q1 2026 Earnings Call Transcript
Motley Fool âĸ 2026-04-28T22:19:39Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $123,239,000 | $109,696,000 | $102,066,000 | $112,212,000 |
| Cost Of Revenue | $123,239,000 | $109,696,000 | $102,066,000 | $112,212,000 |
| Total Revenue | $379,805,000 | $333,785,000 | $280,324,000 | $321,793,000 |
| Operating Revenue | $379,805,000 | $333,785,000 | $280,324,000 | $321,793,000 |
| Expenses | ||||
| Total Expenses | $404,876,000 | $389,320,000 | $387,387,000 | $399,024,000 |
| Other Income Expense | $-5,186,000 | $96,629,000 | $-94,947,000 | $-2,765,000 |
| Other Non Operating Income Expenses | $524,000 | $329,000 | $1,353,000 | $-2,872,000 |
| Net Non Operating Interest Income Expense | $9,174,000 | $11,765,000 | $11,867,000 | $3,762,000 |
| Operating Expense | $281,637,000 | $279,624,000 | $285,321,000 | $286,812,000 |
| Selling And Marketing Expense | $102,643,000 | $81,975,000 | $84,062,000 | $96,027,000 |
| General And Administrative Expense | $107,565,000 | $125,139,000 | $118,838,000 | $100,397,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-21,354,000 | $52,549,000 | $-190,284,000 | $-76,613,000 |
| Net Interest Income | $9,174,000 | $11,765,000 | $11,867,000 | $3,762,000 |
| Interest Income | $9,174,000 | $11,765,000 | $11,867,000 | $3,762,000 |
| Normalized Income | $-16,843,100 | $-43,173,200 | $-114,207,000 | $-76,697,530 |
| Net Income From Continuing And Discontinued Operation | $-21,354,000 | $52,549,000 | $-190,284,000 | $-76,613,000 |
| Total Operating Income As Reported | $-30,781,000 | $40,765,000 | $-203,363,000 | $-77,231,000 |
| Net Income Common Stockholders | $-21,354,000 | $52,549,000 | $-190,284,000 | $-76,613,000 |
| Net Income | $-21,354,000 | $52,549,000 | $-190,284,000 | $-76,613,000 |
| Net Income Including Noncontrolling Interests | $-21,354,000 | $52,549,000 | $-190,284,000 | $-76,613,000 |
| Net Income Continuous Operations | $-21,354,000 | $52,549,000 | $-190,284,000 | $-76,613,000 |
| Pretax Income | $-21,083,000 | $52,859,000 | $-190,143,000 | $-76,234,000 |
| Special Income Charges | $-5,710,000 | $96,300,000 | $-96,300,000 | $0 |
| Interest Income Non Operating | $9,174,000 | $11,765,000 | $11,867,000 | $3,762,000 |
| Operating Income | $-25,071,000 | $-55,535,000 | $-107,063,000 | $-77,231,000 |
| Gross Profit | $256,566,000 | $224,089,000 | $178,258,000 | $209,581,000 |
| Per Share | ||||
| Diluted EPS | $-0.40 | $0.93 | $-3.54 | $-1.44 |
| Basic EPS | $-0.40 | $1.00 | $-3.54 | $-1.44 |
| Other | ||||
| Tax Effect Of Unusual Items | $-1,199,100 | $577,800 | $-20,223,000 | $22,470 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $1,055,000 | $-132,078,000 | $9,061,000 | $-61,331,000 |
| Total Unusual Items | $-5,710,000 | $96,300,000 | $-96,300,000 | $107,000 |
| Total Unusual Items Excluding Goodwill | $-5,710,000 | $96,300,000 | $-96,300,000 | $107,000 |
| Reconciled Depreciation | $20,416,000 | $19,757,000 | $19,824,000 | $16,007,000 |
| EBITDA (Bullshit earnings) | $-4,655,000 | $-35,778,000 | $-87,239,000 | $-61,224,000 |
| EBIT | $-25,071,000 | $-55,535,000 | $-107,063,000 | $-77,231,000 |
| Diluted Average Shares | $53,287,546 | $56,620,590 | $53,764,705 | $53,321,625 |
| Basic Average Shares | $53,287,546 | $52,773,247 | $53,764,705 | $53,321,625 |
| Diluted NI Availto Com Stockholders | $-21,354,000 | $52,549,000 | $-190,284,000 | $-76,613,000 |
| Tax Provision | $271,000 | $310,000 | $141,000 | $379,000 |
| Other Special Charges | $5,710,000 | $-96,300,000 | $96,300,000 | - |
| Research And Development | $71,429,000 | $72,510,000 | $82,421,000 | $90,388,000 |
| Selling General And Administration | $210,208,000 | $207,114,000 | $202,900,000 | $196,424,000 |
| Other Gand A | $107,565,000 | $125,139,000 | $118,838,000 | $100,397,000 |
| Restructuring And Mergern Acquisition | - | $1,783,000 | $2,320,000 | $0 |
| Gain On Sale Of Security | - | - | $10,000 | $107,000 |
Fetched: 2026-06-14
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $230,805,000 | $299,913,000 | $175,291,000 | $350,337,000 |
| Total Assets | $413,228,000 | $491,050,000 | $466,826,000 | $542,991,000 |
| Total Non Current Assets | $156,096,000 | $139,218,000 | $153,113,000 | $155,142,000 |
| Other Non Current Assets | $3,904,000 | $2,806,000 | $1,939,000 | $4,350,000 |
| Goodwill And Other Intangible Assets | $72,296,000 | $78,520,000 | $86,037,000 | $80,574,000 |
| Other Intangible Assets | $31,960,000 | $38,184,000 | $45,701,000 | $43,051,000 |
| Current Assets | $257,132,000 | $351,832,000 | $313,713,000 | $387,849,000 |
| Other Current Assets | $10,591,000 | $7,071,000 | $7,763,000 | $9,216,000 |
| Inventory | $26,705,000 | $19,503,000 | $19,471,000 | $19,232,000 |
| Receivables | $42,628,000 | $64,605,000 | $51,061,000 | $66,312,000 |
| Accounts Receivable | $42,628,000 | $64,605,000 | $51,061,000 | $66,312,000 |
| Cash Cash Equivalents And Short Term Investments | $177,208,000 | $260,653,000 | $235,418,000 | $293,089,000 |
| Cash And Cash Equivalents | $65,429,000 | $114,689,000 | $82,197,000 | $89,921,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $26,194,000 | $28,366,000 | $34,221,000 | $38,997,000 |
| Long Term Debt And Capital Lease Obligation | $19,679,000 | $22,263,000 | $28,278,000 | $33,406,000 |
| Current Debt And Capital Lease Obligation | $6,515,000 | $6,103,000 | $5,943,000 | $5,591,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $110,127,000 | $112,617,000 | $205,498,000 | $112,080,000 |
| Total Non Current Liabilities Net Minority Interest | $20,278,000 | $23,246,000 | $127,426,000 | $36,105,000 |
| Other Non Current Liabilities | $418,000 | $819,000 | $99,012,000 | $249,000 |
| Non Current Deferred Liabilities | $181,000 | $164,000 | $136,000 | $2,418,000 |
| Non Current Deferred Taxes Liabilities | $181,000 | $164,000 | $136,000 | $0 |
| Current Liabilities | $89,849,000 | $89,371,000 | $78,072,000 | $75,975,000 |
| Current Deferred Liabilities | $4,653,000 | $4,848,000 | $5,668,000 | $7,404,000 |
| Payables And Accrued Expenses | $37,074,000 | $40,087,000 | $41,138,000 | $43,737,000 |
| Payables | $9,988,000 | $7,686,000 | $12,872,000 | $9,942,000 |
| Accounts Payable | $9,988,000 | $7,686,000 | $12,872,000 | $9,942,000 |
| Other Current Liabilities | - | $2,540,000 | $5,620,000 | $2,341,000 |
| Derivative Product Liabilities | - | - | $0 | $32,000 |
| Equity | ||||
| Common Stock Equity | $303,101,000 | $378,433,000 | $261,328,000 | $430,911,000 |
| Total Equity Gross Minority Interest | $303,101,000 | $378,433,000 | $261,328,000 | $430,911,000 |
| Stockholders Equity | $303,101,000 | $378,433,000 | $261,328,000 | $430,911,000 |
| Gains Losses Not Affecting Retained Earnings | $-5,515,000 | $-8,569,000 | $-6,963,000 | $-7,503,000 |
| Other Equity Adjustments | $-5,515,000 | $-8,569,000 | $-6,963,000 | $-7,503,000 |
| Retained Earnings | $-735,359,000 | $-626,242,000 | $-678,269,000 | $-460,444,000 |
| Other | ||||
| Ordinary Shares Number | $50,916,644 | $54,771,203 | $51,503,377 | $53,533,250 |
| Share Issued | $50,916,644 | $54,771,203 | $51,503,377 | $53,533,250 |
| Tangible Book Value | $230,805,000 | $299,913,000 | $175,291,000 | $350,337,000 |
| Invested Capital | $303,101,000 | $378,433,000 | $261,328,000 | $430,911,000 |
| Working Capital | $167,283,000 | $262,461,000 | $235,641,000 | $311,874,000 |
| Capital Lease Obligations | $26,194,000 | $28,366,000 | $34,221,000 | $38,997,000 |
| Total Capitalization | $303,101,000 | $378,433,000 | $261,328,000 | $430,911,000 |
| Additional Paid In Capital | $1,043,925,000 | $1,013,193,000 | $946,511,000 | $898,806,000 |
| Capital Stock | $50,000 | $51,000 | $49,000 | $52,000 |
| Common Stock | $50,000 | $51,000 | $49,000 | $52,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $19,679,000 | $22,263,000 | $28,278,000 | $33,406,000 |
| Current Deferred Revenue | $4,653,000 | $4,848,000 | $4,748,000 | $5,342,000 |
| Current Capital Lease Obligation | $6,515,000 | $6,103,000 | $5,943,000 | $5,591,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $38,107,000 | $38,333,000 | $19,703,000 | $16,902,000 |
| Current Provisions | $3,500,000 | - | - | - |
| Current Accrued Expenses | $27,086,000 | $32,401,000 | $28,266,000 | $33,795,000 |
| Investments And Advances | $24,165,000 | $0 | - | - |
| Other Investments | $24,165,000 | $0 | - | - |
| Goodwill | $40,336,000 | $40,336,000 | $40,336,000 | $37,523,000 |
| Net PPE | $55,731,000 | $57,892,000 | $65,137,000 | $70,218,000 |
| Accumulated Depreciation | $-38,851,000 | $-36,942,000 | $-32,263,000 | $-24,424,000 |
| Gross PPE | $94,582,000 | $94,834,000 | $97,400,000 | $94,642,000 |
| Leases | $18,171,000 | $18,106,000 | $18,259,000 | $17,389,000 |
| Construction In Progress | $8,280,000 | $11,937,000 | $8,306,000 | $7,639,000 |
| Other Properties | $22,760,000 | $24,340,000 | $29,891,000 | $34,689,000 |
| Machinery Furniture Equipment | $45,371,000 | $40,451,000 | $40,944,000 | $34,925,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $9,804,000 | $4,819,000 | $3,658,000 | $2,962,000 |
| Work In Process | $3,740,000 | $3,793,000 | $5,191,000 | $4,306,000 |
| Raw Materials | $13,161,000 | $10,891,000 | $10,622,000 | $11,964,000 |
| Other Short Term Investments | $111,779,000 | $145,964,000 | $153,221,000 | $203,168,000 |
Fetched: 2026-06-14
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $35,444,000 | $31,564,000 | $-27,628,000 | $-49,573,000 |
| Operating Activities | ||||
| Operating Cash Flow | $42,032,000 | $38,048,000 | $-18,388,000 | $-25,239,000 |
| Cash Flow From Continuing Operating Activities | $42,032,000 | $38,048,000 | $-18,388,000 | $-25,239,000 |
| Operating Gains Losses | $48,000 | $91,000 | $-250,000 | $-107,000 |
| Investing Activities | ||||
| Capital Expenditure | $-6,588,000 | $-6,484,000 | $-9,240,000 | $-24,334,000 |
| Investing Cash Flow | $2,158,000 | $-483,000 | $40,446,000 | $-228,502,000 |
| Cash Flow From Continuing Investing Activities | $2,158,000 | $-483,000 | $40,446,000 | $-228,502,000 |
| Capital Expenditure Reported | $-5,913,000 | $-6,484,000 | $-8,344,000 | $-21,234,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-87,768,000 | $-522,000 | $-27,541,000 | $-642,000 |
| Financing Cash Flow | $-93,394,000 | $-5,606,000 | $-29,606,000 | $-4,535,000 |
| Cash Flow From Continuing Financing Activities | $-93,394,000 | $-5,606,000 | $-29,606,000 | $-4,535,000 |
| Net Other Financing Charges | $-13,621,000 | $-15,417,000 | $-3,684,000 | $-8,558,000 |
| Net Common Stock Issuance | $-87,768,000 | $-522,000 | $-27,541,000 | $-642,000 |
| Issuance Of Capital Stock | - | - | $0 | $0 |
| Common Stock Issuance | - | - | $0 | $0 |
| Other | ||||
| Income Tax Paid Supplemental Data | $284,000 | $317,000 | $738,000 | $392,000 |
| End Cash Position | $65,980,000 | $115,274,000 | $82,783,000 | $90,443,000 |
| Beginning Cash Position | $115,274,000 | $82,783,000 | $90,443,000 | $348,696,000 |
| Effect Of Exchange Rate Changes | $-90,000 | $532,000 | $-112,000 | $23,000 |
| Changes In Cash | $-49,204,000 | $31,959,000 | $-7,548,000 | $-258,276,000 |
| Proceeds From Stock Option Exercised | $7,995,000 | $10,333,000 | $1,619,000 | $4,665,000 |
| Common Stock Payments | $-87,768,000 | $-522,000 | $-27,541,000 | $-642,000 |
| Net Investment Purchase And Sale | $8,746,000 | $6,001,000 | $56,368,000 | $-203,558,000 |
| Sale Of Investment | $154,671,000 | $166,921,000 | $258,498,000 | $111,587,000 |
| Purchase Of Investment | $-145,925,000 | $-160,920,000 | $-202,130,000 | $-315,145,000 |
| Net Business Purchase And Sale | $0 | $0 | $-6,682,000 | $-610,000 |
| Purchase Of Business | $0 | $0 | $-6,682,000 | $-610,000 |
| Net Intangibles Purchase And Sale | $-675,000 | $0 | $-896,000 | $-3,100,000 |
| Purchase Of Intangibles | $-675,000 | $0 | $-896,000 | $-3,100,000 |
| Change In Working Capital | $3,807,000 | $-102,120,000 | $106,029,000 | $-14,217,000 |
| Change In Other Current Liabilities | $-5,997,000 | $-5,863,000 | $-5,418,000 | $-3,456,000 |
| Change In Payables And Accrued Expense | $-3,345,000 | $-82,104,000 | $93,610,000 | $22,000 |
| Change In Accrued Expense | $-4,153,000 | $-76,994,000 | $90,706,000 | $2,076,000 |
| Change In Payable | $808,000 | $-5,110,000 | $2,904,000 | $-2,054,000 |
| Change In Account Payable | $808,000 | $-5,110,000 | $2,904,000 | $-2,054,000 |
| Change In Prepaid Assets | $-4,413,000 | $606,000 | $1,767,000 | $-1,049,000 |
| Change In Inventory | $-4,959,000 | $-1,018,000 | $54,000 | $-2,859,000 |
| Change In Receivables | $22,521,000 | $-13,741,000 | $16,016,000 | $-6,660,000 |
| Changes In Account Receivables | $22,521,000 | $-13,741,000 | $16,016,000 | $-6,660,000 |
| Other Non Cash Items | $703,000 | $931,000 | $568,000 | $727,000 |
| Stock Based Compensation | $34,864,000 | $66,406,000 | $49,086,000 | $46,553,000 |
| Asset Impairment Charge | $2,258,000 | $0 | $1,000,000 | $840,000 |
| Amortization Of Securities | $1,273,000 | $621,000 | $-4,927,000 | $390,000 |
| Deferred Tax | $17,000 | $-187,000 | $566,000 | - |
| Deferred Income Tax | $17,000 | $-187,000 | $566,000 | - |
| Depreciation Amortization Depletion | $20,416,000 | $19,757,000 | $19,824,000 | $16,007,000 |
| Depreciation And Amortization | $20,416,000 | $19,757,000 | $19,824,000 | $16,007,000 |
| Depreciation | $20,416,000 | $19,757,000 | $19,824,000 | $16,007,000 |
| Net Income From Continuing Operations | $-21,354,000 | $52,549,000 | $-190,284,000 | $-76,613,000 |
| Interest Paid Supplemental Data | - | $0 | $0 | $8,000 |
| Change In Other Working Capital | - | $-187,000 | $566,000 | $-215,000 |
| Unrealized Gain Loss On Investment Securities | - | $0 | $0 | $1,181,000 |
| Repayment Of Debt | - | - | $0 | $0 |
| Net Issuance Payments Of Debt | - | - | $0 | $0 |
| Net Long Term Debt Issuance | - | - | $0 | $0 |
| Long Term Debt Payments | - | - | $0 | $0 |
| Gain Loss On Investment Securities | - | - | $-294,000 | $-107,000 |
Fetched: 2026-06-14